rifamycins - CISMeF

Preferred Label : rifamycins;

MeSH definition : A group of ANTI-BACTERIAL AGENTS characterized by a chromophoric naphthohydroquinone group spanned by an aliphatic bridge not previously found in other known ANTI-BACTERIAL AGENTS. They have been isolated from fermentation broths of Streptomyces mediterranei.;

MeSH synonym : rifomycins;

CISMeF synonym : Rifamycin; Rifomycin;

Wikipedia link : https://en.wikipedia.org/wiki/Rifamycin;

Codes EINECS : 230-273-3;

Is substance : O;

Details

Origin ID

D012294;

UMLS CUI

C0035609;

ATC code(s)
- antibiotics [ATC Code]
- rifamycin [ATC Code]
- rifamycin [ATC Code]
ATC code(s)
- rifamycin [ATC Code]
- rifamycin [ATC Code]
- rifamycin [ATC Code]
- rifamycin [ATC Code]
- rifamycin [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Currated CISMeF NLP mapping
- Medicinal product containing rifamycin structure and acting as antibacterial agent (product) [SNOMED CT concept]
- Rifamycin [ICD-11 Extension code]
- Rifamycin [ICHI extension code]
- Rifamycin [SMS substance]
- Rifamycin [NCIt concept]
- Rifamycin (substance) [SNOMED CT concept]
- Substance with rifamycin structure (substance) [SNOMED CT concept]
- rifamycin [Substance BNPC]
False automatic mappings
- Poisoning by, adverse effect of and underdosing of rifampicins [ICD-10 Sub-category]
- Rifamycins [ICD-10 Sub-category (who)]
- Rifamycins [ICD-10 Sub-category (who)]
Pharmacological action(s)
- anti-bacterial agents [MeSH Descriptor]
Record concept(s)
- rifamycins [MeSH concept]
Related MeSH Supplementary Concept(s)
- 16,17-dihydro-17-hydroxyrifamycin S [MeSH Supplementary Concept]
- 16,17-dihydrorifamycin S [MeSH Supplementary Concept]
- 25-deacetoxy-25-hydroxyrifamycin S [MeSH Supplementary Concept]
- 27-O-demethylrifamycin S [MeSH Supplementary Concept]
- 27-O-demethylrifamycin SV [MeSH Supplementary Concept]
- 3-((dimethylhydrazono)methyl)rifamycin SV [MeSH Supplementary Concept]
- 3-(4-cinnamylpiperazinyl iminomethyl)rifamycin SV [MeSH Supplementary Concept]
- 3-amino-4-iminorifamycin S [MeSH Supplementary Concept]
- 3-carbomethoxy rifamycin S [MeSH Supplementary Concept]
- 3-formyl-25-desacetylrifamycin [MeSH Supplementary Concept]
- 3-formylrifamycin SV [MeSH Supplementary Concept]
- 3-hydrazinorifamycin [MeSH Supplementary Concept]
- 31-homorifamycin W [MeSH Supplementary Concept]
- 32-hydroxyrifalazil [MeSH Supplementary Concept]
- 4-deoxy-3'-bromopyrido(1',2'-1,2)imidazo(5,4-c)rifamycin S [MeSH Supplementary Concept]
- ABI 0043 [MeSH Supplementary Concept]
- ABI 1131 [MeSH Supplementary Concept]
- ABI 1657 [MeSH Supplementary Concept]
- AF 013 [MeSH Supplementary Concept]
- C 27 [MeSH Supplementary Concept]
- CBR 2092 [MeSH Supplementary Concept]
- CGP 27557 [MeSH Supplementary Concept]
- CGP 29861 [MeSH Supplementary Concept]
- CGP 4832 [MeSH Supplementary Concept]
- CGP 7040 [MeSH Supplementary Concept]
- FCE 22250 [MeSH Supplementary Concept]
- FCE 22807 [MeSH Supplementary Concept]
- KRM 1648 [MeSH Supplementary Concept]
- KRM 1657 [MeSH Supplementary Concept]
- KRM 1668 [MeSH Supplementary Concept]
- KRM 1671 [MeSH Supplementary Concept]
- R 761 [MeSH Supplementary Concept]
- TNP-2092 [MeSH Supplementary Concept]
- benzothiazole-rifamycin [MeSH Supplementary Concept]
- chaxamycin A [MeSH Supplementary Concept]
- chaxamycin D [MeSH Supplementary Concept]
- cytotrienin A [MeSH Supplementary Concept]
- halomicin B [MeSH Supplementary Concept]
- halomicins [MeSH Supplementary Concept]
- juanlimycin A [MeSH Supplementary Concept]
- juanlimycin B [MeSH Supplementary Concept]
- kanglemycin A [MeSH Supplementary Concept]
- kanglemycin C [MeSH Supplementary Concept]
- proansamycin B [MeSH Supplementary Concept]
- protorifamycin I [MeSH Supplementary Concept]
- reprimun [MeSH Supplementary Concept]
- rifamdin [MeSH Supplementary Concept]
- rifametane [MeSH Supplementary Concept]
- rifamexil [MeSH Supplementary Concept]
- rifamide [MeSH Supplementary Concept]
- rifamycin B [MeSH Supplementary Concept]
- rifamycin L [MeSH Supplementary Concept]
- rifamycin O [MeSH Supplementary Concept]
- rifamycin P [MeSH Supplementary Concept]
- rifamycin Q [MeSH Supplementary Concept]
- rifamycin S [MeSH Supplementary Concept]
- rifamycin SV [MeSH Supplementary Concept]
- rifamycin verde [MeSH Supplementary Concept]
- rifazone-82 [MeSH Supplementary Concept]
- rifocort [MeSH Supplementary Concept]
- salinisporamycin [MeSH Supplementary Concept]
- tolypomycin Y [MeSH Supplementary Concept]
- tolypomycinone [MeSH Supplementary Concept]
Semantic type(s)
- Antibiotic [UMLS semantic type]
- Organic Chemical [UMLS semantic type]
UMLS correspondences (same concept)
- Substance with rifamycin structure (substance) [SNOMED CT concept]
Validated automatic mappings to BTNT
- rifamycin [ATC Code]
- rifamycin [ATC Code]
- rifamycin [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients